Last reviewed · How we verify
ABT-SLV187
ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function.
ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function. Used for Hypertension, Chronic kidney disease.
At a glance
| Generic name | ABT-SLV187 |
|---|---|
| Also known as | DUOPA™ (carbidopa and levodopa Enteral Suspension), DUODOPA®, Levodopa-carbidopa intestinal gel (LCIG) |
| Sponsor | AbbVie |
| Drug class | Soluble epoxide hydrolase (sEH) inhibitor |
| Target | Soluble epoxide hydrolase (sEH) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug works by blocking soluble epoxide hydrolase, an enzyme that breaks down endogenous anti-inflammatory lipid mediators called EETs. By inhibiting this enzyme, ABT-SLV187 allows EETs to accumulate, which promotes vasodilation, reduces inflammation, and improves endothelial function. This mechanism is being explored for cardiovascular and renal protective effects in various disease states.
Approved indications
- Hypertension
- Chronic kidney disease
Common side effects
- Headache
- Dizziness
- Gastrointestinal disturbances
Key clinical trials
- A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) (PHASE3)
- An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications (PHASE3)
- A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) (PHASE3)
- A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications (PHASE3)
- Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact (PHASE4)
- Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-SLV187 CI brief — competitive landscape report
- ABT-SLV187 updates RSS · CI watch RSS
- AbbVie portfolio CI